AI Engines For more Details: Perplexity Kagi Labs You
Analgesic Effects: Isopyrin hydrochloride is used to relieve pain, including headaches, muscle aches, toothaches, and menstrual pain. It works by inhibiting the synthesis of prostaglandins, which are substances in the body that promote inflammation and pain.
Antipyretic Effects: Isopyrin hydrochloride is also used to reduce fever. It acts on the hypothalamus in the brain, which regulates body temperature, to lower elevated body temperature.
Antispasmodic Effects: In some formulations, isopyrin hydrochloride may be combined with antispasmodic agents to relieve muscle spasms and cramps associated with conditions such as irritable bowel syndrome (IBS) or menstrual cramps.
Side Effects: Common side effects of isopyrin hydrochloride may include gastrointestinal disturbances such as nausea, vomiting, and stomach pain. In rare cases, allergic reactions such as skin rash or difficulty breathing may occur. Long-term or excessive use of isopyrin hydrochloride may lead to adverse effects such as gastrointestinal ulcers, kidney damage, or liver toxicity.
Drug Interactions: Isopyrin hydrochloride may interact with other medications, including blood thinners (such as warfarin), corticosteroids, and other nonsteroidal anti-inflammatory drugs (NSAIDs). Combining isopyrin hydrochloride with these medications may increase the risk of gastrointestinal bleeding or other adverse effects.
Contraindications: Isopyrin hydrochloride is contraindicated in individuals with a history of gastrointestinal ulcers, bleeding disorders, severe liver or kidney disease, or hypersensitivity to the drug or its components. It should be used with caution in elderly individuals and those with pre-existing medical conditions.
Pregnancy and Lactation: Isopyrin hydrochloride should be used with caution during pregnancy, especially in the third trimester, as it may increase the risk of complications such as premature closure of the fetal ductus arteriosus. It may also be excreted in breast milk, so breastfeeding mothers should consult a healthcare professional before using it.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.4 | 1.2 | -2 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alzheimer's disease | 0.7 | 1 | -0.43 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.3 | 0.67 |
| Ankylosing spondylitis | 0.6 | 0.9 | -0.5 |
| Anorexia Nervosa | 0.3 | 1 | -2.33 |
| Asthma | 0.7 | 0.3 | 1.33 |
| Atherosclerosis | 0.7 | 0.7 | |
| Atrial fibrillation | 1 | 0.3 | 2.33 |
| Autism | 0.7 | 1.4 | -1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.3 | 1 |
| Brain Trauma | 0.6 | -0.6 | |
| Breast Cancer | 0.3 | -0.3 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 0.4 | 0.9 | -1.25 |
| Cerebral Palsy | 0.3 | 0.6 | -1 |
| Chronic Fatigue Syndrome | 1.2 | 0.6 | 1 |
| Chronic Kidney Disease | 0.3 | 0.3 | 0 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | -0.3 | |
| Chronic Urticaria (Hives) | 0.1 | -0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.6 | 0.6 | |
| Colorectal Cancer | 0.7 | 0.3 | 1.33 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 0.3 | 0.4 | -0.33 |
| COVID-19 | 0.6 | 1.6 | -1.67 |
| Crohn's Disease | 0.7 | 1.4 | -1 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.4 | 0.6 | -0.5 |
| Depression | 1.6 | 1.5 | 0.07 |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.3 | 0.6 | -1 |
| Epilepsy | 0.4 | 0.3 | 0.33 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.3 | -0.3 | |
| Functional constipation / chronic idiopathic constipation | 1 | 0.7 | 0.43 |
| gallstone disease (gsd) | 0.4 | 0.4 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 0.3 | 0.3 | 0 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.6 | 0.6 | 0 |
| Gulf War Syndrome | 0.1 | -0.1 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.7 | 0.6 | 0.17 |
| Heart Failure | 1 | 0.3 | 2.33 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.9 | 1.1 | -0.22 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.4 | 0.5 |
| Inflammatory Bowel Disease | 0.4 | 1.6 | -3 |
| Insomnia | 0.3 | 0.9 | -2 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.7 | 0.9 | -0.29 |
| ischemic stroke | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 0.7 | 0.6 | 0.17 |
| Long COVID | 0.6 | 1.9 | -2.17 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | -0.3 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Metabolic Syndrome | 0.7 | 0.7 | 0 |
| Mood Disorders | 1.6 | 1.5 | 0.07 |
| Multiple Sclerosis | 0.3 | 1.1 | -2.67 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.6 | -0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 0.9 | 0 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 0.9 | 1.6 | -0.78 |
| obsessive-compulsive disorder | 1.3 | 0.3 | 3.33 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 1.1 | 1 | 0.1 |
| Polycystic ovary syndrome | 1.4 | 1.2 | 0.17 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 0.4 | 0.3 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 0.4 | 2.75 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 0.9 | 0.9 | 0 |
| scoliosis | 0.7 | -0.7 | |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | 0 |
| Systemic Lupus Erythematosus | 0.4 | 0.6 | -0.5 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.7 | 0.9 | -0.29 |
| Type 2 Diabetes | 0.7 | 0.7 | 0 |
| Ulcerative colitis | 0.7 | 0.7 | 0 |
| Unhealthy Ageing | 0.4 | 0.4 | |
| Vitiligo | 1 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
